Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis

Abstract

Purpose: With increasing environmental pollution, the incidence of allergic conjunctivitis is increasing. Newer anti-allergic medications with combined anti-histaminic and mast cell stabilization action can help reducing the use of topical steroids for milder form of disease. There is no study directly comparing olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) for mild to moderate allergic conjunctivitis cases. Hence, we decided to methodically study the efficacy of three topical medications. Methods: Prospective, observer-masked clinical trial enrolled 45 patients with 15 patients in each of the three groups. Patients with mild to moderate allergic conjunctivitis were sequentially assigned to respective groups, and relief of symptoms and signs were noted upto 1-month follow-up. Results: All three topical medications faired almost equally in resolving symptoms of the patients with mild to moderate allergic conjunctivitis, and most of them reported complete relief after 1 week of use of medication. Few cases with limbal or palpebral papillae reported symptomatic relief after use of medication, but the resolution of these signs was not noted in all three groups. Conclusion: We concluded similar efficacy of three medications in relieving symptoms and inefficacy in regressing palpebral and limbal papillae in cases of allergic conjunctivitis.

Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis

“…A comparative study done by Dudeja I, et al concluded Alcaftadine 0.25%, olopatadine 0.2%, and bepotastine 1.5% eye drops have been proved to be safe and well-tolerated topical medication for allergic conjunctivitis. [ 9 ] This study resounded the same, and the medications were found to be safe, with minimal transient side effects of burning sensation and taste impairment noticed by a few patients (more in group 1 and group 3, respectively). Most patients responded to treatment and were willing to continue the eye drop, if indicated.…”

“…Total Ocular Symptom Scoring System (TOSS) scoring was used to grade the signs and symptoms. All patients aged between 18 and 60 years belonging to either gender, with mild-to-moderate allergic conjunctivitis [ Table 1 ][ 9 ] presenting to outpatient department between July 2019 and September 2019 were included after obtaining written informed consent.…”

“…A deviation of ±1 a day for the first follow-up and ±2 days for subsequent follow-up was accepted. At each follow-up visit data on concomitant medications, ocular symptoms and ocular signs using hyperaemia score [ Table 2 ][ 9 ] graded by slit-lamp examination by the investigator and adverse events (AEs) were collected. In case of relapse, the patient was asked to visit OPD on Day 21.…”

To evaluate the efficacy and safety of olopatadine 0.1% ophthalmic solution and bepotastine 1.5% ophthalmic solution in patients with vernal keratoconjunctivitis in a tertiary care hospital

“…[ 23 24 ] Bepotastine is a less commonly used drug. [ 25 26 ] In this review, we seek to assess the two medications and evaluate their effectiveness in treating Spring Catarrh. For this study, different signs and symptoms of VKC were used as criteria for assessment.…”

Topical cyclosporine versus allergen specific immunotherapy in perennial allergic conjunctivitis

“…1st, 3rd, and 6th month signs’ of the participants were evaluated from medical records. The four signs, papillary reaction, limbal involvement, corneal involvement, and conjunctival hyperemia were graded using the 4-point system (0, none; 1, mild; 2, moderate; and 3 severe) as defined by Uchio et al [ 15 ] and similar to the system used in the study by Dudeja et al [ 16 ]; and the groups were compared using this scoring system. The upper and lower extreme scores were as follows: for upper tarsal papillae, 0 indicates no papillae and 3 indicates predominance of Giant papillae; for limbal activity, 0 indicates no activity and 3 indicates the presence of Horner-Trantas dots; for corneal involvement, 0 indicates intact corneal epithelium and 3 indicates diffuse punctate keratopathy; for conjunctival hyperemia, 0 indicates absence of dilated blood vessels in conjunctiva and 3 indicates generalized dilation of blood vessels.…”